Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trials
SKIN The Journal of Cutaneous Medicine（2023）
摘要
N/A
更多查看译文
关键词
palmoplantar psoriasis,allosteric tyrosine kinase,inhibitor
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要